Table 2 Baseline characteristics grouped by MRSA therapy
Overall (n = 80,330) | MRSA therapy (n = 29,254) | No MRSA therapy (n = 51,076) | P-value* | |
|---|---|---|---|---|
Patient age (years), median (IQR) | 78 (72–83) | 78 (73–83) | 77 (72–83) | 0.1016 |
Male, % | 98.3 | 98.3 | 98.3 | 0.6847 |
Race, % | ||||
White | 81.1 | 79.1 | 82.3 | < 0.0001 |
Black | 13.1 | 15.4 | 11.7 | < 0.0001 |
Other | 5.8 | 5.5 | 6.0 | < 0.0001 |
Hispanic ethnicity, % | 7.0 | 8.0 | 6.4 | < 0.0001 |
MRSA risk score variables, % (1 point, unless noted) | ||||
Age >79 | 43.8 | 44.0 | 43.7 | 0.3867 |
Hospitalization in the past 90 days (2 points) | 27.8 | 33.7 | 24.5 | < 0.0001 |
Intensive care unit admission (2 points) | 21.1 | 29.3 | 16.4 | < 0.0001 |
Outpatient IV antibiotic therapy in past 90 days | 4.9 | 5.3 | 4.7 | 0.0001 |
Nursing home resident in last 90 days | 1.0 | 1.1 | 0.9 | 0.0028 |
Cerebrovascular disease | 18.1 | 19.6 | 17.3 | < 0.0001 |
Dementia | 5.2 | 5.8 | 4.9 | < 0.0001 |
Female with diabetes mellitus | 0.4 | 0.4 | 0.4 | 0.8129 |
MRSA risk score, median (IQR) | 1 (0–3) | 2 (1–3) | 1 (0–2) | < 0.0001 |
Low (0–1), % | 51.4 | 41.6 | 57.0 | < 0.0001 |
Medium (2–5), % | 47.3 | 56.4 | 42.1 | < 0.0001 |
High (6–10), % | 1.3 | 2.1 | 0.9 | < 0.0001 |
Charlson comorbidity score, median (IQR) | 2 (1–4) | 3 (1–4) | 2 (1–4) | < 0.0001 |
Comorbid conditions, % | ||||
Myocardial infarction | 7.2 | 7.6 | 7.0 | 0.0020 |
Heart failure | 25.9 | 27.0 | 25.3 | < 0.0001 |
Chronic obstructive pulmonary disease | 48.7 | 45.5 | 50.5 | < 0.0001 |
Liver disease | 1.3 | 1.5 | 1.2 | 0.0035 |
Renal disease | 14.1 | 17.2 | 12.3 | < 0.0001 |
Diabetes | 30.5 | 31.8 | 29.8 | < 0.0001 |
Neoplastic disease | 25.2 | 26.2 | 24.7 | < 0.0001 |
HIV/AIDS | 0.2 | 0.3 | 0.2 | 0.0961 |
Medication use within 90 days, % | ||||
Cardiovascular medications | 66.5 | 64.9 | 67.3 | < 0.0001 |
Anti-diabetic medications | 22.2 | 22.6 | 22.1 | 0.0852 |
Inhaled corticosteroids | 21.1 | 18.9 | 22.4 | < 0.0001 |
Systemic corticosteroids a | 22.2 | 21.8 | 22.5 | 0.0217 |
Pulmonary medications | 34.8 | 31.4 | 36.8 | < 0.0001 |
Vasopressors, % | 10.2 | 15.2 | 7.2 | < 0.0001 |
Invasive mechanical ventilation, % | 11.1 | 16.3 | 8.2 | < 0.0001 |
Noninvasive mechanical ventilation, % | 4.0 | 5.7 | 3.1 | < 0.0001 |
Hemodialysis, % | 18.3 | 22.7 | 15.7 | < 0.0001 |
Organ failure, % | ||||
Any organ failure, % | 32.2 | 41.8 | 26.7 | < 0.0001 |
Respiratory | 14.4 | 19.4 | 11.5 | < 0.0001 |
Cardiovascular | 9.7 | 13.0 | 7.8 | < 0.0001 |
Neurological | 2.5 | 3.3 | 2.0 | < 0.0001 |
Renal | 20.1 | 26.8 | 16.2 | < 0.0001 |
Hematologic | 4.1 | 5.5 | 3.3 | < 0.0001 |
Hepatic | 0.7 | 0.9 | 0.6 | < 0.0001 |
Antibiotic therapy, % | ||||
Guideline-concordant CAP therapy | 64.1 | 64.9 | 63.6 | 0.0001 |
Pseudomonal therapy | 17.5 | 31.1 | 9.7 | < 0.0001 |
Atypical therapy | 75.2 | 83.6 | 70.5 | < 0.0001 |